Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Peter Young

Physician Assistant Kalispell, MT Physician Assistant

NPI 1295207363 CMS profile 6161598

40 Four Mile Dr Ste 7, Kalispell, MT 59901

Open in the dashboard

General payments

$3,121

73 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Young of Kalispell, MT is reported in the CMS Open Payments database as having received $3,121 across 73 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,731 62
2023 General $118 2
2022 General $1,173 8
2021 General $99 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Young
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Peter Young were reported at $1,731. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Peter Young Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $99 $132 $37–$438 $132
2022 $1,173 $155 $48–$522 $149
2023 $118 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $1,731 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Genzyme Corporation $493 4 payments
  2. Incyte Corporation $471 12 payments
  3. AbbVie, Inc. $437 15 payments
  4. Arcutis Biotherapeutics, Inc. $397 11 payments
  5. Regeneron Healthcare Solutions, Inc. $355 11 payments
  6. Galderma Laboratories, L.P. $268 2 payments
  7. Sun Pharmaceutical Industries Inc. $169 4 payments
  8. UCB, Inc. $143 4 payments
  9. Amgen Inc. $141 3 payments
  10. Janssen Scientific Affairs, LLC $107 1 payment
  11. Other $142 6 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,606 70 payments
  2. Consulting Fee $406 1 payment
  3. Education $110 2 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $514 5 payments
  2. OPZELURA $471 12 payments
  3. Zoryve $397 11 payments
  4. DUPIXENT Immunology And Inflammation $355 11 payments
  5. AKLIEF $268 2 payments
  6. SKYRIZI Immunology $165 9 payments
  7. TREMFYA $157 3 payments
  8. RINVOQ $154 4 payments
  9. SKYRIZI Immunology $93 1 payment
  10. Bimzelx $58 3 payments
  11. Other $201 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

992

Median for Physician Assistant: 241

Drug cost

$233,374

Median for Physician Assistant: $4,110

Branded share of claims

6.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 36 $127,211
Otezla Apremilast Brand 14 $61,970
Calcipotriene Generic 146 $14,383
Fluorouracil Generic 124 $4,927
Clobetasol Propionate Generic 116 $4,625
Tacrolimus Generic 46 $3,003
Pimecrolimus Generic 16 $2,932
Triamcinolone Acetonide Generic 84 $2,520
Betamethasone Dipropionate Generic 18 $2,293
Doxycycline Monohydrate Generic 77 $2,024

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Records

73 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record